Lv1
48 积分 2023-04-28 加入
恶性胸腔积液干预性临床研究设计专家共识
2个月前
已完结
Eftilagimod Alpha (Soluble LAG3 Protein) Combined with Pembrolizumab as Second-Line Therapy for Patients with Metastatic Head and Neck Squamous Cell Carcinoma
3个月前
已完结
Neoadjuvant immunotherapy and oncolytic virotherapy in HPV positive and HPV negative skin cancer: A comprehensive review
3个月前
已完结
Design and validation of the first-in-class PROTACs for targeted degradation of the immune checkpoint LAG-3
4个月前
已完结
Pleural effusion is a negative prognostic factor for immunotherapy in patients with non-small cell lung cancer (NSCLC): The pluie study
5个月前
已完结
Improving dual targeting selectivity in T-cell engagers via synapse-gated and affinity-tuned trispecific antibody design
7个月前
已关闭
Clinical Pharmacology Characterization of Bispecific T-Cell Engagers: A Summary Based on FDA Approvals
7个月前
已完结
PLT012, a Humanized CD36-Blocking Antibody, Is Effective for Unleashing Antitumor Immunity Against Liver Cancer and Liver Metastasis
7个月前
已完结
代谢相关(非酒精性)脂肪性肝病防治指南(2024年版)
8个月前
已完结
T细胞免疫疗法治疗侵袭性B细胞淋巴瘤中国专家共识（2025年版）
8个月前
已完结
皖公网安备34019202002308
